dc.contributor.author | Gutierrez-Gutierrez, Belen | |
dc.contributor.author | Bonomo, Robert A. | |
dc.contributor.author | Carmeli, Yehuda | |
dc.contributor.author | Paterson, David L. | |
dc.contributor.author | Almirante, Benito | |
dc.contributor.author | Martinez-Martinez, Luis | |
dc.contributor.author | Oliver, Antonio | |
dc.contributor.author | Calbo, Esther | |
dc.contributor.author | Pena, Carmen | |
dc.contributor.author | Akova, Murat | |
dc.contributor.author | Pitout, Johann | |
dc.contributor.author | Origuen, Julia | |
dc.contributor.author | Pintado, Vicente | |
dc.contributor.author | Garcia-Vazquez, Elisa | |
dc.contributor.author | Gasch, Oriol | |
dc.contributor.author | Hamprecht, Axel | |
dc.contributor.author | Prim, Nuria | |
dc.contributor.author | Tumbarello, Mario | |
dc.contributor.author | Bou, German | |
dc.contributor.author | Viale, Pierluigi | |
dc.contributor.author | Tacconelli, Evelina | |
dc.contributor.author | Almela, Manel | |
dc.contributor.author | Perez, Federico | |
dc.contributor.author | Giamarellou, Helen | |
dc.contributor.author | Miguel Cisneros, Jose | |
dc.contributor.author | Schwaber, Mitchell J. | |
dc.contributor.author | Venditti, Mario | |
dc.contributor.author | Lowman, Warren | |
dc.contributor.author | Bermejo, Joaquin | |
dc.contributor.author | Hsueh, Po-Ren | |
dc.contributor.author | Mora-Rillo, Marta | |
dc.contributor.author | Gracia-Ahulfinger, Irene | |
dc.contributor.author | Pascual, Alvaro | |
dc.contributor.author | Rodriguez-Bano, Jesus | |
dc.date.accessioned | 2019-12-10T11:12:35Z | |
dc.date.available | 2019-12-10T11:12:35Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 0305-7453 | |
dc.identifier.uri | https://doi.org/10.1093/jac/dkv502 | |
dc.identifier.uri | http://hdl.handle.net/11655/15035 | |
dc.description.abstract | Objectives: Data about the efficacy of ertapenem for the treatment of bloodstream infections (BSI) due to ESBL-producing Enterobacteriaceae (ESBL-E) are Limited. We compared the clinical efficacy of ertapenem and other carbapenems in monomicrobial BSI due to ESBL-E. Methods: A multinational retrospective cohort study (INCREMENT project) was performed (ClinicalTrials.gov identifier: NCT01764490). Patients given monotherapy with ertapenem or other carbapenems were compared. Empirical and targeted therapies were analysed. Propensity scores were used to control for confounding; sensitivity analyses were performed in subgroups. The outcome variables were cure/improvement rate at day 14 and all-cause 30 day mortality. Results: The empirical therapy cohort (ETC) and the targeted therapy cohort (TTC) included 195 and 509 patients, respectively. Cure/improvement rates were 90.6% with ertapenem and 75.5% with other carbapenems (P=0.06) in the ETC and 89.8% and 82.6% (P=0.02) in the TTC, respectively; 30 day mortality rates were 3.1% and 23.3% (P=0.01) in the ETC and 9.3% and 17.1% (P=0.01) in the TTC, respectively. Adjusted ORs (95% CI) for cure/improvement with empirical and targeted ertapenem were 1.87 (0.24-20.08; P=0.58) and 1.04 (0.442.50; P=0.92), respectively. For the propensity-matched cohorts it was 1.18 (0.43-3.29; P=0.74). Regarding 30 day mortality, the adjusted HR (95% CI) for targeted ertapenem was 0.93 (0.43-2.03; P=0.86) and for the propensity-matched cohorts it was 1.05 (0.46-2.44; P=0.90). Sensitivity analyses were consistent except for patients with severe sepsis/septic shock, which showed a non-significant trend favouring other carbapenems. Conclusions: Ertapenem appears as effective as other carbapenems for empirical and targeted therapy of BSI due to ESBL-E, but further studies are needed for patients with severe sepsis/septic shock. | |
dc.language.iso | en | |
dc.publisher | Oxford Univ Press | |
dc.relation.isversionof | 10.1093/jac/dkv502 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Infectious Diseases | |
dc.subject | Microbiology | |
dc.subject | Pharmacology & Pharmacy | |
dc.title | Ertapenem For The Treatment Of Bloodstream Infections Due To Esbl-Producing Enterobacteriaceae: A Multinational Pre-Registered Cohort Study | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Journal Of Antimicrobial Chemotherapy | |
dc.contributor.department | İç Hastalıkları | |
dc.identifier.volume | 71 | |
dc.identifier.issue | 6 | |
dc.identifier.startpage | 1672 | |
dc.identifier.endpage | 1680 | |
dc.description.index | WoS | |
dc.description.index | Scopus | |